Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0298 -0.0051 (-14.61%)
Streaming Delayed Price Updated: 12:45 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Warrant

< Previous 1 2 3 Next >
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of SARS-CoV-2 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Full Year 2022
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
Conference to take place Feb. 6-9 in New York 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.